Developer docs
API playgroundTry for free, no card

Search company profiles

Adalvo

Full company profile

uuid0007p49

Namestring
Adalvo
Legal namestring
Adalvo Limited
Websiteurl
adalvo.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Adalvo is a B2B pharmaceutical company founded in 2018 by Anil Okay and headquartered in San Gwann, Malta. It develops pharmaceutical dossiers and out-licenses the resulting products to commercial partners, operating an end-to-end platform spanning R&D, regulatory affairs, manufacturing, and global commercialization. Its portfolio includes over 90 small-molecule generic products, more than 15 value-added 505(b)(2) formulations (with a CNS focus), and over 8 peptide products (including GLP-1s) targeting Oncology, Women's Health, Cardiovascular, CNS, anti-infectives, dermatology, and rare diseases, with one of the broadest diabetes portfolios in the industry. The company repeatedly secures European DCP and U.S. 505(b)(2) approvals, including first-to-market launches such as generic Brivaracetam in Croatia, generic Ivermectin cream in Germany (Europe's first generic alternative to Soolantra), and a pan-European Day-1 launch of generic Nintedanib Soft Gel Capsules.

Adalvo's business model is partner-centric and asset-light: it monetizes through licensing fees, milestone payments, and supply arrangements with a network of 170+ commercial partners across 140+ markets, and does not sell directly to patients. Distribution is executed through partners including Cipla (South Africa, U.S., Canada), STADA (Germany), Blanver (Brazil and LATAM), Cosmo Pharmaceuticals, SoliPharma, and Azurity Pharmaceuticals, alongside several European regional generic and value-added players. The company holds a co-developed proprietary complex topical formulation platform with SoliPharma and an EU patent on Lisdexamfetamine oral solution that was successfully defended before the EPO Opposition Division in February 2026. Headcount sits at 251-500, with claimed EBITDA doubling annually since inception.

The corporate timeline is recent but inflection-heavy. In July 2025, EQT acquired a majority stake in Adalvo from Aztiq (completing the transaction in October 2025) — an exit that represented Metric Capital's largest to date — providing the capital base for the next expansion phase. In August 2025, Adalvo announced the (partially completed) acquisition of a four-product branded pharmaceutical portfolio from Sandoz across 60+ markets, extending its model beyond dossier out-licensing. The leadership team has been rebuilt for scale, with new CFO Joan Fusté (effective 1 January 2025), CSCO Nick Kelly (effective 1 January 2025), and CLO Rannveig Borg Sigurðardóttir (appointed June 2026), joining existing senior leadership including Deputy CEO/CSO Martina Feitzinger, COO Andreas Kopp, CCO Arni Baldursson, Chief IP Officer Toni Santamaria, and a regional network of Business Development Directors covering Southern Europe, North/West Europe, LATAM, MENA, Brazil, APAC, and South-East Asia.

Short descriptiontext

Adalvo is a Malta-based B2B pharmaceutical company developing and out-licensing generic, 505(b)(2), and peptide dossiers to 170+ commercial partners across 140+ markets. PE-backed by EQT since 2025, it ranks among the top three global B2B dossier developers with a broad specialty generics pipeline.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersSan Gwann, Malta
HQ citystring
San Gwann
HQ countrystring
Malta
HQ regionstring
Europe
Markets served

Serves global market

Offices15 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, pharmaceutical out-licensing, dossier development, value-added medicines, specialty generics
Industry3 codes
PRIMARYHLAIAJAH
Biologics & Biosimilars Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Generic Pharmaceuticals (B2B dossier development and out-licensing)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Out-licensing
TypeLicensing Royalties
Description

Adalvo develops dossiers and out-licenses products to commercial partners across 140+ markets. Revenue is generated through licensing fees, milestone payments, and supply arrangements with partners.

adalvo.com
2Product Development and Commercialization
TypeProfessional Services
Description

End-to-end services from R&D through manufacturing to global commercialization, generating revenue through development fees, regulatory milestones, and product supply to partners.

adalvo.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Adalvo operates as a global B2B pharmaceutical company that develops dossiers and out-licenses generic, value-added 505(b)(2), peptide, and biosimilar pharmaceutical products to 170+ commercial partners across 140+ markets. The company runs an end-to-end platform spanning R&D, regulatory filing, manufacturing, and global commercialization, executing Day-1 launches following regulatory exclusivity expiry across Europe and international markets. Its portfolio covers specialty small molecules (90+), value-added 505(b)(2) products (15+), peptides including GLP-1s (8+), and 30+ differentiated technologies across oncology, CNS, women's health, cardiovascular, dermatology, anti-infectives, and rare diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 69 Marketing Authorisation Approvals in January 2024 alone
+5 more records
Product overview1 text field

Adalvo is a global B2B pharmaceutical company that operates as an end-to-end platform from R&D to manufacturing with superior capabilities in market access and global commercialization. The company offers a diversified portfolio across multiple therapeutic areas and product types: (1) Specialty Gx portfolio with 90+ small-molecule offerings focused on Oncology, Women's Health, Cardiovascular, and CNS; (2) Value-added 505(b)(2) portfolio with 15+ products focused on CNS; (3) Peptide portfolio with 8+ products focused on Rare Diseases and Diabetes; (4) Extensive generic pharmaceutical products including Letermovir, Linagliptin/Metformin, Dolutegravir, Tacrolimus, Avatrombopag, Brivaracetam, Ivermectin, Nintedanib, Tafamidis, Binimetinib, Apalutamide, Palbociclib, Semaglutide, and others; (5) Complex generics, peptides, and GLP-1s. The company specializes in dossier development and out-licensing across 140+ markets with 170+ commercial partners.

Product and service24 records
1Rifamycin SV MMX 200 mg (Aemcolo)
CategoryGeneric pharmaceutical product
Description

Antibiotic designed to target the colon directly with reduced impact on gut bacteria, for traveler's diarrhea treatment. Marketed by Adalvo through joint launch with Cosmo Pharmaceuticals N.V.

2Generic Brivaracetam film-coated tablets
CategoryGeneric pharmaceutical product
Description

Adjunctive therapy for partial-onset seizures in adults, adolescents, and children from age 2 with epilepsy. First generic Brivaracetam in Europe.

3Generic Ivermectin 10mg/g (1%) cream
CategoryGeneric pharmaceutical product
Description

Topical treatment for inflammatory lesions associated with rosacea with dual anti-inflammatory and antiparasitic mechanism. First generic alternative to Soolantra in Europe.

4Nintedanib Soft Gel Capsules
CategoryGeneric pharmaceutical product
Description

Tyrosine kinase inhibitor for Idiopathic Pulmonary Fibrosis (IPF), Chronic Fibrosing Interstitial Lung Diseases (PF-ILD), Systemic Sclerosis-Associated ILD (SSc-ILD), and Non-Small Cell Lung Cancer (NSCLC).

5Generic Palbociclib film-coated tablets
CategoryGeneric pharmaceutical product
Description

First-line therapy for breast cancer; DCP approved in EU.

6Generic Linagliptin 5mg film-coated tablet
CategoryGeneric pharmaceutical product
Description

DPP-4 inhibitor for type 2 diabetes; DCP approved with Spanish MA.

7Generic Tacrolimus topical ointment (0.03% and 0.1%)
CategoryGeneric pharmaceutical product
Description

Non-corticosteroid therapy for moderate to severe atopic dermatitis (eczema); approved across EU markets.

8Generic Afatinib film-coated tablets (20, 30, 40, 50 mg)
CategoryGeneric pharmaceutical product
Description

Generic film-coated tablets in 20, 30, 40, and 50 mg strengths; EU marketing authorisation via DCP.

9Generic Azacitidine tablets
CategoryGeneric pharmaceutical product
Description

For oral maintenance therapy for patients with acute myeloid leukaemia; DCP approved.

10ARYNTA (Lisdexamfetamine dimesylate) Oral Solution
CategoryBrand/Value-added product
Description

Ready-to-use oral liquid for ADHD medication; available in the US through Azurity Pharmaceuticals.

11Onsolis (Fentanyl Citrate Buccal Film)
CategoryBrand/Value-added product
Description

For breakthrough cancer pain; a clinically established option for cancer patients.

12Generic Rivaroxaban
CategoryGeneric pharmaceutical product
Description

Anticoagulant product launched across multiple global regions through strategic partners.

13Generic Apremilast
CategoryGeneric pharmaceutical product
Description

For psoriatic arthritis and moderate-to-severe plaque psoriasis; Day-1 EU launch secured.

14Generic Dapagliflozin
CategoryGeneric pharmaceutical product
Description

Blockbuster diabetes and cardiovascular treatment with first European launch in UK.

15Azelastine/Fluticasone nasal spray
CategoryGeneric pharmaceutical product
Description

Based on Dymista reference brand, for seasonal and perennial allergic rhinitis; launched in European markets.

16Adapalene + Benzoyl Peroxide 0.1%/2.5% gel
CategoryGeneric pharmaceutical product
Description

For acne treatment; launched in UK.

17Vyfocis capsules
CategoryBrand product
Description

Addresses recognized clinical need with high-quality, affordable medicines; launched in South Africa with Cipla.

18Value-add oncology product line (two technically differentiated products)
CategoryValue-added oncology portfolio
Description

Two technically differentiated value-add oncology products distributed in Latin America through Blanver partnership.

19Complex topical dermatology product (SoliPharma collaboration)
CategoryGeneric pharmaceutical product (complex topical)
Description

High-barrier, first-to-file topical dermatology asset developed with SoliPharma's proprietary topical formulation platform for global markets.

20Differentiated oncology asset (US 505(b)(2) / Canada Value-Added Medicine)
CategoryValue-added product (505(b)(2))
Description

Technically differentiated oncology asset for the United States (505(b)(2) filing) and Canada (Value-Added Medicine), partnered with Cipla USA Inc. for distribution.

21Sandoz branded product portfolio (four products across 60+ markets)
CategoryBranded product portfolio
Description

Four well-established branded pharmaceutical products acquired from Sandoz across more than 60 markets, including Tegundin and others.

22Specialty Gx small-molecule portfolio (90+ products)
CategorySpecialty generic portfolio
Description

Over 90 small-molecule portfolio offerings across Oncology, Women's Health, Cardiovascular & CNS therapeutic areas available for out-licensing and supply to global partners.

23Value-Added 505(b)(2) portfolio (15+ products)
CategoryValue-added 505(b)(2) portfolio
Description

Value-added product portfolio with 15+ products and a strong focus on CNS, including differentiated formulations.

24Peptide portfolio (8+ products including GLP-1s)
CategoryPeptide portfolio (including GLP-1)
Description

8+ peptide portfolio with a focus on Rare Diseases and Diabetes, including GLP-1s such as Semaglutide.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1Rannveig Borg Sigurðardóttir (Chief Legal Officer)
Strategic tierMinorTypeOthersAnnounced on2026-06-08
Description

Appointment of Rannveig Borg Sigurðardóttir as Chief Legal Officer, based in Switzerland, reporting directly to CEO Anil Okay. She brings over 20 years of international legal leadership spanning M&A, capital markets, corporate governance, compliance, and strategic commercial negotiations.

adalvo.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-19
Description

Strategic distribution partnership with Brazilian pharmaceutical company Blanver for two technically differentiated, value-add oncology products. This agreement strengthens Adalvo's growing presence in Latin America and demonstrates commitment to expanding access to high-quality, complex medicines through best-in-class commercial partners.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-14
Description

Expanded strategic partnership for the launch of Vyfocis® capsules in South Africa, representing a significant step in both companies' commitment to the South African market. Also includes distribution partnership for North America (US and Canada) bringing a technically differentiated oncology asset to patients.

4Joan Fusté (Chief Financial Officer)
Strategic tierMinorTypeOthersAnnounced on2026-04-30
Description

Appointment of Joan Fusté as Chief Financial Officer, bringing over 20 years of finance leadership experience across private equity-backed companies and multinational corporations in the pharmaceutical and healthcare industries.

adalvo.com
5Nick Kelly (Chief Supply Chain Officer)
Strategic tierMinorTypeOthersAnnounced on2026-04-30
Description

Appointment of Nick Kelly as Chief Supply Chain Officer, with more than two decades of supply chain leadership across the pharmaceutical sector spanning branded, generic, and medical device organisations.

adalvo.com
6SoliPharma (Hangzhou SoliPharma Co., Ltd.)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-27
Description

Exclusive global development, licence and supply collaboration for a complex topical dermatology product. Combines SoliPharma's deep expertise in topical and transdermal formulation science with Adalvo's proven track record in bringing complex, high-barrier pharmaceutical products to global markets. Both companies are actively exploring expanding the collaboration across additional topical and specialty pharmaceutical products.

adalvo.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-23
Description

Partnership with STADA, one of Europe's leading generics and branded medicines companies, for the commercial launch of generic Ivermectin 10mg/g (1%) cream in Germany — believed to be Europe's first generic alternative to Soolantra (Galderma).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-01
Description

Joint launch of Rifamycin SV MMX 200 mg (Aemcolo) in September 2023 between Malta-based Adalvo and Ireland-based Cosmo Pharmaceuticals N.V. Rifamycin SV MMX is an antibiotic designed to target the colon directly with reduced impact on gut bacteria, addressing traveler's diarrhea treatment.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Commercial partnership with Azurity Pharmaceuticals for the availability of ARYNTA™ (lisdexamfetamine dimesylate) Oral Solution in the U.S. market, offering a ready-to-use oral liquid option for ADHD medication.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Private European generics and specialty pharma company with a strong B2B out-licensing and Day-1 launch focus across Europe. Highly comparable as both companies target differentiated generics and value-added medicines through channel partnerships.

TypeDirect peer
Description

Polish generics and API manufacturer with broad European footprint and out-licensing model. Comparable as a European-headquartered B2B pharmaceutical company developing generic dossiers and supplying partners across multiple markets.

TypeDirect peer
Description

Slovenian generic pharmaceutical company with strong European, Eastern European, and CIS market presence. Comparable as a European generics player with broad product portfolio and out-licensing/distribution partnerships in 70+ markets.

4Sandoz Group
TypeBroad incumbent
Description

Global generics and biosimilars leader spun off from Novartis with significantly larger scale. Comparable as a major global generics and biosimilars player; Adalvo actually acquired four branded products from Sandoz in 2025.

TypeOthers
Description

Biosimilars-focused sister company from the same founding ecosystem (Adalvo CEO Anil Okay was CCO at Alvotech). Related through shared history and leadership, with overlapping B2B pharmaceutical capabilities in biosimilars vs. Adalvo's generics.

TypeDirect peer
Description

Indian-headquartered global generics manufacturer with strong dossier development, API integration, and out-licensing capabilities. Comparable as a vertically integrated generics player with Day-1 launch expertise across multiple therapeutic areas.

TypeDirect peer
Description

India-based global pharmaceutical company with branded generics, specialty, and out-licensing businesses. Comparable as a B2B pharmaceutical company with global dossier development and differentiated formulation strategies.

TypeBroad incumbent
Description

World's largest generic drug manufacturer with global distribution and broad therapeutic portfolio. Comparable as a leading global generics player, though much larger scale; competes for Day-1 launch opportunities and partner relationships.

TypeBroad incumbent
Description

Global pharmaceutical company formed by Mylan-Upjohn combination with extensive generics and branded portfolio. Comparable as a global generics heavyweight with multi-market regulatory and commercial infrastructure that overlaps with Adalvo's partner network.

TypeOthers
Description

Privately-held US-based generics and specialty pharma company; originally the parent ecosystem for Adalvo's founding team. Comparable as a B2B-focused pharmaceutical company with private equity backing and global generics portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Adalvo

Generic Pharmaceuticals (B2B dossier development and out-licensing)adalvo.com

Adalvo is a Malta-based B2B pharmaceutical company developing and out-licensing generic, 505(b)(2), and peptide dossiers to 170+ commercial partners across 140+ markets. PE-backed by EQT since 2025, it ranks among the top three global B2B dossier developers with a broad specialty generics pipeline.

What Adalvo does

Adalvo is a B2B pharmaceutical company founded in 2018 by Anil Okay and headquartered in San Gwann, Malta. It develops pharmaceutical dossiers and out-licenses the resulting products to commercial partners, operating an end-to-end platform spanning R&D, regulatory affairs, manufacturing, and global commercialization. Its portfolio includes over 90 small-molecule generic products, more than 15 value-added 505(b)(2) formulations (with a CNS focus), and over 8 peptide products (including GLP-1s) targeting Oncology, Women's Health, Cardiovascular, CNS, anti-infectives, dermatology, and rare diseases, with one of the broadest diabetes portfolios in the industry. The company repeatedly secures European DCP and U.S. 505(b)(2) approvals, including first-to-market launches such as generic Brivaracetam in Croatia, generic Ivermectin cream in Germany (Europe's first generic alternative to Soolantra), and a pan-European Day-1 launch of generic Nintedanib Soft Gel Capsules.

Adalvo's business model is partner-centric and asset-light: it monetizes through licensing fees, milestone payments, and supply arrangements with a network of 170+ commercial partners across 140+ markets, and does not sell directly to patients. Distribution is executed through partners including Cipla (South Africa, U.S., Canada), STADA (Germany), Blanver (Brazil and LATAM), Cosmo Pharmaceuticals, SoliPharma, and Azurity Pharmaceuticals, alongside several European regional generic and value-added players. The company holds a co-developed proprietary complex topical formulation platform with SoliPharma and an EU patent on Lisdexamfetamine oral solution that was successfully defended before the EPO Opposition Division in February 2026. Headcount sits at 251-500, with claimed EBITDA doubling annually since inception.

The corporate timeline is recent but inflection-heavy. In July 2025, EQT acquired a majority stake in Adalvo from Aztiq (completing the transaction in October 2025) — an exit that represented Metric Capital's largest to date — providing the capital base for the next expansion phase. In August 2025, Adalvo announced the (partially completed) acquisition of a four-product branded pharmaceutical portfolio from Sandoz across 60+ markets, extending its model beyond dossier out-licensing. The leadership team has been rebuilt for scale, with new CFO Joan Fusté (effective 1 January 2025), CSCO Nick Kelly (effective 1 January 2025), and CLO Rannveig Borg Sigurðardóttir (appointed June 2026), joining existing senior leadership including Deputy CEO/CSO Martina Feitzinger, COO Andreas Kopp, CCO Arni Baldursson, Chief IP Officer Toni Santamaria, and a regional network of Business Development Directors covering Southern Europe, North/West Europe, LATAM, MENA, Brazil, APAC, and South-East Asia.

Adalvo firmographics

Firmographics
Name
Adalvo
Legal name
Adalvo Limited
Website
https://adalvo.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
251–500 employees
Short description
Adalvo is a Malta-based B2B pharmaceutical company developing and out-licensing generic, 505(b)(2), and peptide dossiers to 170+ commercial partners across 140+ markets. PE-backed by EQT since 2025, it ranks among the top three global B2B dossier developers with a broad specialty generics pipeline.
Ownership category
akta.pro rank

Adalvo industry classification

Industry
Product category
Generic Pharmaceuticals (B2B dossier development and out-licensing)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAJAH
Biologics & Biosimilars Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)

Keywords

  • Generic pharmaceuticals
  • Pharmaceutical out-licensing
  • Dossier development
  • Value-added medicines
  • Specialty generics

Where Adalvo is headquartered

Location

Headquarters

HQ city
San Gwann
HQ country
Malta
HQ region
Europe

Offices15 records

Markets served

Adalvo business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing and Out-licensing: Adalvo develops dossiers and out-licenses products to commercial partners across 140+ markets. Revenue is generated through licensing fees, milestone payments, and supply arrangements with partners.
  2. Product Development and Commercialization: End-to-end services from R&D through manufacturing to global commercialization, generating revenue through development fees, regulatory milestones, and product supply to partners.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels4 records

Adalvo product offering

Product offering

Core offering

Adalvo operates as a global B2B pharmaceutical company that develops dossiers and out-licenses generic, value-added 505(b)(2), peptide, and biosimilar pharmaceutical products to 170+ commercial partners across 140+ markets. The company runs an end-to-end platform spanning R&D, regulatory filing, manufacturing, and global commercialization, executing Day-1 launches following regulatory exclusivity expiry across Europe and international markets. Its portfolio covers specialty small molecules (90+), value-added 505(b)(2) products (15+), peptides including GLP-1s (8+), and 30+ differentiated technologies across oncology, CNS, women's health, cardiovascular, dermatology, anti-infectives, and rare diseases.

Product overview

Adalvo is a global B2B pharmaceutical company that operates as an end-to-end platform from R&D to manufacturing with superior capabilities in market access and global commercialization. The company offers a diversified portfolio across multiple therapeutic areas and product types: (1) Specialty Gx portfolio with 90+ small-molecule offerings focused on Oncology, Women's Health, Cardiovascular, and CNS; (2) Value-added 505(b)(2) portfolio with 15+ products focused on CNS; (3) Peptide portfolio with 8+ products focused on Rare Diseases and Diabetes; (4) Extensive generic pharmaceutical products including Letermovir, Linagliptin/Metformin, Dolutegravir, Tacrolimus, Avatrombopag, Brivaracetam, Ivermectin, Nintedanib, Tafamidis, Binimetinib, Apalutamide, Palbociclib, Semaglutide, and others; (5) Complex generics, peptides, and GLP-1s. The company specializes in dossier development and out-licensing across 140+ markets with 170+ commercial partners.

Differentiator

Problem solved

Functional benefit

Products and services

  • Rifamycin SV MMX 200 mg (Aemcolo) Antibiotic designed to target the colon directly with reduced impact on gut bacteria, for traveler's diarrhea treatment. Marketed by Adalvo through joint launch with Cosmo Pharmaceuticals N.V.
  • Generic Brivaracetam film-coated tablets Adjunctive therapy for partial-onset seizures in adults, adolescents, and children from age 2 with epilepsy. First generic Brivaracetam in Europe.
  • Generic Ivermectin 10mg/g (1%) cream Topical treatment for inflammatory lesions associated with rosacea with dual anti-inflammatory and antiparasitic mechanism. First generic alternative to Soolantra in Europe.
  • Nintedanib Soft Gel Capsules Tyrosine kinase inhibitor for Idiopathic Pulmonary Fibrosis (IPF), Chronic Fibrosing Interstitial Lung Diseases (PF-ILD), Systemic Sclerosis-Associated ILD (SSc-ILD), and Non-Small Cell Lung Cancer (NSCLC).
  • Generic Palbociclib film-coated tablets First-line therapy for breast cancer; DCP approved in EU.
  • Generic Linagliptin 5mg film-coated tablet DPP-4 inhibitor for type 2 diabetes; DCP approved with Spanish MA.
  • Generic Tacrolimus topical ointment (0.03% and 0.1%) Non-corticosteroid therapy for moderate to severe atopic dermatitis (eczema); approved across EU markets.
  • Generic Afatinib film-coated tablets (20, 30, 40, 50 mg) Generic film-coated tablets in 20, 30, 40, and 50 mg strengths; EU marketing authorisation via DCP.
  • Generic Azacitidine tablets For oral maintenance therapy for patients with acute myeloid leukaemia; DCP approved.
  • ARYNTA (Lisdexamfetamine dimesylate) Oral Solution Ready-to-use oral liquid for ADHD medication; available in the US through Azurity Pharmaceuticals.
  • Onsolis (Fentanyl Citrate Buccal Film) For breakthrough cancer pain; a clinically established option for cancer patients.
  • Generic Rivaroxaban Anticoagulant product launched across multiple global regions through strategic partners.
  • Generic Apremilast For psoriatic arthritis and moderate-to-severe plaque psoriasis; Day-1 EU launch secured.
  • Generic Dapagliflozin Blockbuster diabetes and cardiovascular treatment with first European launch in UK.
  • Azelastine/Fluticasone nasal spray Based on Dymista reference brand, for seasonal and perennial allergic rhinitis; launched in European markets.
  • Adapalene + Benzoyl Peroxide 0.1%/2.5% gel For acne treatment; launched in UK.
  • Vyfocis capsules Addresses recognized clinical need with high-quality, affordable medicines; launched in South Africa with Cipla.
  • Value-add oncology product line (two technically differentiated products) Two technically differentiated value-add oncology products distributed in Latin America through Blanver partnership.
  • Complex topical dermatology product (SoliPharma collaboration) High-barrier, first-to-file topical dermatology asset developed with SoliPharma's proprietary topical formulation platform for global markets.
  • Differentiated oncology asset (US 505(b)(2) / Canada Value-Added Medicine) Technically differentiated oncology asset for the United States (505(b)(2) filing) and Canada (Value-Added Medicine), partnered with Cipla USA Inc. for distribution.
  • Sandoz branded product portfolio (four products across 60+ markets) Four well-established branded pharmaceutical products acquired from Sandoz across more than 60 markets, including Tegundin and others.
  • Specialty Gx small-molecule portfolio (90+ products) Over 90 small-molecule portfolio offerings across Oncology, Women's Health, Cardiovascular & CNS therapeutic areas available for out-licensing and supply to global partners.
  • Value-Added 505(b)(2) portfolio (15+ products) Value-added product portfolio with 15+ products and a strong focus on CNS, including differentiated formulations.
  • Peptide portfolio (8+ products including GLP-1s) 8+ peptide portfolio with a focus on Rare Diseases and Diabetes, including GLP-1s such as Semaglutide.

Quantifiable outcome

  • 69 Marketing Authorisation Approvals in January 2024 alone
  • +5 more outcomes

Companies that use Adalvo

Customer profile

Named customers5 records

Segments1 record

Ideal customer profiles1 record

Adalvo technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Adalvo partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered minor and core.

  • Rannveig Borg Sigurðardóttir (Chief Legal Officer)minorOthers · 8 June 2026Appointment of Rannveig Borg Sigurðardóttir as Chief Legal Officer, based in Switzerland, reporting directly to CEO Anil Okay. She brings over 20 years of international legal leadership spanning M&A, capital markets, corporate governance, compliance, and strategic commercial negotiations.
  • BlanvercoreChannel Partner/ Reseller/ Distributor · 19 May 2026Strategic distribution partnership with Brazilian pharmaceutical company Blanver for two technically differentiated, value-add oncology products. This agreement strengthens Adalvo's growing presence in Latin America and demonstrates commitment to expanding access to high-quality, complex medicines through best-in-class commercial partners.
  • CiplacoreChannel Partner/ Reseller/ Distributor · 14 May 2026Expanded strategic partnership for the launch of Vyfocis® capsules in South Africa, representing a significant step in both companies' commitment to the South African market. Also includes distribution partnership for North America (US and Canada) bringing a technically differentiated oncology asset to patients.
  • Joan Fusté (Chief Financial Officer)minorOthers · 30 April 2026Appointment of Joan Fusté as Chief Financial Officer, bringing over 20 years of finance leadership experience across private equity-backed companies and multinational corporations in the pharmaceutical and healthcare industries.
  • Nick Kelly (Chief Supply Chain Officer)minorOthers · 30 April 2026Appointment of Nick Kelly as Chief Supply Chain Officer, with more than two decades of supply chain leadership across the pharmaceutical sector spanning branded, generic, and medical device organisations.
  • SoliPharma (Hangzhou SoliPharma Co., Ltd.)coreStrategic or Co-development Partner · 27 April 2026Exclusive global development, licence and supply collaboration for a complex topical dermatology product. Combines SoliPharma's deep expertise in topical and transdermal formulation science with Adalvo's proven track record in bringing complex, high-barrier pharmaceutical products to global markets. Both companies are actively exploring expanding the collaboration across additional topical and specialty pharmaceutical products.
  • STADAcoreChannel Partner/ Reseller/ Distributor · 23 April 2026Partnership with STADA, one of Europe's leading generics and branded medicines companies, for the commercial launch of generic Ivermectin 10mg/g (1%) cream in Germany — believed to be Europe's first generic alternative to Soolantra (Galderma).
  • Cosmo Pharmaceuticals N.V.coreStrategic or Co-development Partner · 1 September 2023Joint launch of Rifamycin SV MMX 200 mg (Aemcolo) in September 2023 between Malta-based Adalvo and Ireland-based Cosmo Pharmaceuticals N.V. Rifamycin SV MMX is an antibiotic designed to target the colon directly with reduced impact on gut bacteria, addressing traveler's diarrhea treatment.
  • Azurity PharmaceuticalsminorChannel Partner/ Reseller/ DistributorCommercial partnership with Azurity Pharmaceuticals for the availability of ARYNTA™ (lisdexamfetamine dimesylate) Oral Solution in the U.S. market, offering a ready-to-use oral liquid option for ADHD medication.

Scale indicators14 records

Recent moves7 records

Expansion highlights8 records

Adalvo competitors and assessment

Company assessment

Direct peers

  • Stada Arzneimittel: Private European generics and specialty pharma company with a strong B2B out-licensing and Day-1 launch focus across Europe. Highly comparable as both companies target differentiated generics and value-added medicines through channel partnerships.
  • Polpharma Group: Polish generics and API manufacturer with broad European footprint and out-licensing model. Comparable as a European-headquartered B2B pharmaceutical company developing generic dossiers and supplying partners across multiple markets.
  • Krka: Slovenian generic pharmaceutical company with strong European, Eastern European, and CIS market presence. Comparable as a European generics player with broad product portfolio and out-licensing/distribution partnerships in 70+ markets.
  • Aurobindo Pharma: Indian-headquartered global generics manufacturer with strong dossier development, API integration, and out-licensing capabilities. Comparable as a vertically integrated generics player with Day-1 launch expertise across multiple therapeutic areas.
  • Glenmark Pharmaceuticals: India-based global pharmaceutical company with branded generics, specialty, and out-licensing businesses. Comparable as a B2B pharmaceutical company with global dossier development and differentiated formulation strategies.

Broad incumbents

  • Sandoz Group: Global generics and biosimilars leader spun off from Novartis with significantly larger scale. Comparable as a major global generics and biosimilars player; Adalvo actually acquired four branded products from Sandoz in 2025.
  • Teva Pharmaceutical Industries: World's largest generic drug manufacturer with global distribution and broad therapeutic portfolio. Comparable as a leading global generics player, though much larger scale; competes for Day-1 launch opportunities and partner relationships.
  • Viatris: Global pharmaceutical company formed by Mylan-Upjohn combination with extensive generics and branded portfolio. Comparable as a global generics heavyweight with multi-market regulatory and commercial infrastructure that overlaps with Adalvo's partner network.

Others

  • Alvotech: Biosimilars-focused sister company from the same founding ecosystem (Adalvo CEO Anil Okay was CCO at Alvotech). Related through shared history and leadership, with overlapping B2B pharmaceutical capabilities in biosimilars vs. Adalvo's generics.
  • Alvogen: Privately-held US-based generics and specialty pharma company; originally the parent ecosystem for Adalvo's founding team. Comparable as a B2B-focused pharmaceutical company with private equity backing and global generics portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Adalvo social profiles

Digital presence

Adalvo financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Adalvo leadership team

Management profile

Number of profiles

Profiles16 records

Adalvo funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Adalvo M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adalvo

What does Adalvo do?

Adalvo operates as a global B2B pharmaceutical company that develops dossiers and out-licenses generic, value-added 505(b)(2), peptide, and biosimilar pharmaceutical products to 170+ commercial partners across 140+ markets. The company runs an end-to-end platform spanning R&D, regulatory filing, manufacturing, and global commercialization, executing Day-1 launches following regulatory exclusivity expiry across Europe and international markets. Its portfolio covers specialty small molecules (90+), value-added 505(b)(2) products (15+), peptides including GLP-1s (8+), and 30+ differentiated technologies across oncology, CNS, women's health, cardiovascular, dermatology, anti-infectives, and rare diseases.

Is Adalvo a public or private company?

Adalvo is a private company. It is classified as private equity controlled and is currently operating.

When was Adalvo founded?

Adalvo was founded in 2020. It employs 251 to 500 people.

Where is Adalvo based?

Adalvo is headquartered in San Gwann, Malta, in the Europe region.

How does Adalvo make money?

Two revenue lines are on record. Licensing and Out-licensing is the primary driver. The others are product Development and Commercialization.

Who are Adalvo's main competitors?

Direct peers on record are Stada Arzneimittel, Polpharma Group, Krka, Aurobindo Pharma and Glenmark Pharmaceuticals. Broad incumbents are Sandoz Group, Teva Pharmaceutical Industries and Viatris. Others are Alvotech and Alvogen.

Does Adalvo have an API?

No public API is recorded for Adalvo.

What industry is Adalvo in?

Adalvo's product category is Generic Pharmaceuticals (B2B dossier development and out-licensing). Its primary akta.pro industry code is HLAIAJAH, Biologics & Biosimilars Distributors, with a secondary code of HLAIABAG, Generic APIs & Intermediates (Active Ingredients). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
News-MedicalAdalvo expands biosimilars portfolio through acquisition of romiplostim biosimilar program from EnzeneAdalvo acquired Enzene's romiplostim biosimilar program, referencing Nplate, to expand its biosimilars portfolio. The reference product generated about $1.5 billion in global sales in 2025. Enzene will continue development and manufacturing, including regulatory filings with the US FDA and EMA.The Pharma LetterAdalvo and Gedeon Richter expand collaboration to tirzepatideAdalvo and Gedeon Richter expanded their global partnership to co-develop and supply tirzepatide-based therapies for type 2 diabetes and obesity. The collaboration builds on their earlier partnership around Wegovy (semaglutide) and targets one of the fastest-growing therapeutic areas.The Pharma LetterSandoz wins approval for new semaglutide treatment option in BrazilSandoz confirmed ANVISA granted marketing authorization for Owozy (semaglutide) for type-2 diabetes in Brazil, to be commercialized with Adalvo. The pre-filled pen is among the first new semaglutide options in a $1.8 billion market, with an expected launch in the second half of 2026.Drug Store NewsFDA to review Amneal's, Adalvo's 2 ANDAs for generic tirzepatide autoinjectorAmneal and Adalvo announced that the FDA has accepted for review two Abbreviated New Drug Applications for generic tirzepatide injection, referencing Eli Lilly's Mounjaro and Zepbound, seeking approval for single-dose prefilled pen presentations for Type 2 diabetes and chronic weight management indications. The companies are jointly developing these generic autoinjector products for the U.S. market, with Amneal leading all commercialization efforts while combining Adalvo's product development expertise with Amneal's regulatory and commercial infrastructure. This acceptance marks a milestone in the partnership to advance complex generic medicines and expand future treatment options for patients.EIN PresswireAdalvo Appoints Rannveig Borg Sigurðardóttir as Chief Legal OfficerAdalvo appointed Rannveig Borg Sigurðardóttir as Chief Legal Officer, reporting to CEO Anil Okay. She brings over 20 years of international legal leadership and joins a team driving expansion with over 170 commercial partners.openPR.comKey Factors and Emerging Trends Shaping the Traveler's Diarrhea Treatment Market LandscapeThe Business Research Company published a market report forecasting the traveler's diarrhea treatment market to reach $2.31 billion by 2030, growing at a compound annual growth rate of 7.7%. The report identifies key growth drivers including rising focus on preventive travel healthcare, wider adoption of probiotics and zinc supplements, and higher demand for child-specific treatments. In September 2023, Malta-based Adalvo Ltd. and Ireland-based Cosmo Pharmaceuticals N.V. jointly launched Rifamycin SV MMX 200 mg (Aemcolo), an antibiotic designed to target the colon directly with reduced impact on gut bacteria.GlobeNewswireAztiq sells Adalvo to EQTAztiq sold the majority of its stake in Adalvo to EQT, a global investment organization. Adalvo, founded in 2018, has over 280 employees and 170 commercial partnerships in more than 140 countries. The transaction is expected to close in H2 2025.AdalvoEQT Signs Definitive Agreement to Acquire Adalvo, To Drive Its Next Phase of GrowthEQT signed a definitive agreement to acquire a majority stake in Adalvo, a B2B pharmaceutical dossier developer. Adalvo, founded in 2018, operates in over 140 markets with 170+ commercial partners and a portfolio of 130+ medicines. EQT aims to support Adalvo's growth toward becoming the top B2B pharmaceutical company.AInvestEQT's Strategic Acquisition of Adalvo and the Future of B2B Generic Pharmaceuticals: A Catalyst for Sustained Growth in a Dynamic SectorEQT acquired Adalvo, a B2B generic pharma leader with 120+ medicines and 60% EBITDA CAGR, in July 2025. The partnership aims to scale operations and accelerate innovation in niche therapeutics. The move positions Adalvo to capture market share in cost-effective generics amid rising demand.PR NewswireEQT to acquire Adalvo, a leading B2B dossier developerEQT agreed to acquire a majority stake in Adalvo, a B2B dossier developer for generic drugs. The deal is expected to close in H2 2025, with EQT investing in R&D and supply chain. Adalvo has partnered with over 170 generic companies in more than 140 countries.